Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
The FDA will rule on a low dose of zongertinib in the summer.
US approval could mark the company's graduation to oncology.
A triplet did worse than control in first-line kidney cancer.
Meanwhile, Tango tries again in PRMT5.
Halda, Accent and Vividion take more projects into phase 1.
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
